
0:00
18:13
The best place to begin: the highest-yield topic in the exam, at the pace the rest of the series runs. What the screening trials really show and why they only look contradictory, the MRI-first pathway and biparametric scanning, why the biopsy left the operating theatre, the T2 change people miss, who actually needs staging imaging, why three surgery-versus-monitoring trials disagree, when a benign biopsy is not reassuring, and the two recurrence definitions you must not mix up.
More episodes from "FRCS in 15"



Don't miss an episode of “FRCS in 15” and subscribe to it in the GetPodcast app.







